Dummer, R; Biette, K; Gusenleitner, D; Ramesh, R; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Gasal, E; Brase, JC; Long, GV.
Effect of first-line spartalizumab plus dabrafenib plus trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma.
J CLIN ONCOL. 2020; 38(15):-ASCO 2020; May 29-31, 2020; Chicago.
[Poster]
Web of Science